Fourth booster now available for people living with diabetes 3 June 2022 A winter or fourth booster of the Covid vaccine is now available and free to all people in Australia managing their diabetes with medication following advocacy by Diabetes Australia. The Australian Technical Advisory Group on Immunisation (ATAGI) is advising the winter COVID-19 dose can be administered at the same time as the influenza vaccine. Diabetes Australia Group CEO Justine Cain wrote to ATAGI on May 16 urging it to expand availability of fourth booster doses of Covid-19 vaccine to Australians living with diabetes. People with diabetes are at greater risk of becoming severely ill or being hospitalised if they contract Covid-19 or the flu. “People living with diabetes need the same access to these vaccines as those living with other chronic conditions. We were grateful that the latest update from ATAGI addressed these concerns,” Ms Cain said. ATAGI has recommended a Covid-19 booster at least four months after the previous booster dose or four months after a previous Covid-19 infection. You are eligible for a fourth booster if you meet the below criteria: · Adults aged 65 years and older · Residents 16 years and older of aged care or disability care facilities · People aged 16 years and older who are severely immunocompromised (as defined in the ATAGI statement on use of a 3rd primary dose of COVID-19 vaccine) · Aboriginal and Torres Strait Islander adults aged 50 years and older. The expanded criteria now applies to people aged 16-64 years who have a medical condition that increases the risk of severe Covid-19 illness, including diabetes. Also included are people with disability with significant or complex health needs or multiple comorbidities which increase the risk of poor outcomes from Covid-19. For more information, click here
Blog 27 July 2026 Round up for Diabetes Australia and turn small change into impact Learn how your spare change with Round up goes straight to Diabetes Australia to support programs, research, education, and advocacy. Continue Reading
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading
Blog 22 July 2026 Living Out Loud: how Australia spoke up for National Diabetes Week 2026 From 12 to 18 July, Australians living with diabetes, alongside their carers, researchers, health professionals and clinicians, did something powerful. They... Continue Reading